StephenGarrettMarcusMD

Summary

• Stephen Marcus, M.D., is a physician and pharmaceutical executive who has led the development of several innovative and highly profitable pharmaceutical and biotechnology products. Dr. Marcus is the Chief Executive Officer of Cantex Pharmaceuticals, a clinical stage pharmaceutical company developing novel treatments of pancreatic cancer, glioblastoma, brain metastasis, and breast cancer.
  
  Dr. Marcus led the development of Betaseron, the first disease-modifying therapy for multiple sclerosis and, with this major development, a disabling disease for which there was no treatment became treatable. Dr. Marcus was instrumental in the development of the cancer treatment medications Fludarabine (for chronic lymphocytic leukemia), Intron A (for multiple myeloma, follicular lymphoma, and melanoma), Temodar (for malignant brain tumors), brand-equivalent Paclitaxel (for metastatic breast cancer) and the early development of oral cladribine (Mavenclad), another multiple sclerosis treatment.
  
  Cantex Pharmaceuticals is developing azeliragon, an orally administered small molecule, administered once daily, that inhibits RAGE interactions with its natural ligands. Cantex has ongoing clinical trials in metastatic pancreatic cancer, glioblastoma, brain metastasis, neoadjuvant therapy of breast cancer, and hospitalized patients with pneumonia to prevent acute kidney injury. These trials are based on robust pre-clinical data as well as on extensive clinical safety information from randomized placebo-controlled clinical trials.